Global Autologous CAR-T Cell Therapy Market Strategic Research Report

Scope of the Report

The global Autologous CAR-T Cell Therapy market size is predicted to grow from US$ 5,204 million in 2025 to US$ 21,530 million in 2032; it is expected to grow at a CAGR of 22.9% from 2026 to 2032.

CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.

Cell immunotherapy techniques, represented by chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), express CAR fusion proteins on the surface of T cells through genetic engineering technology. The CAR extracellular antigen recognition region (one of the components of CAR cells, responsible for recognizing tumor cell surface antigens) can specifically recognize tumor antigens and transmit signals into cells to activate T cells, achieving proliferation and targeted killing of tumor cells. CAR-T therapy has shown breakthrough efficacy and enormous potential for development and market prospects for cancer patients who are unable to cope with traditional treatments. CAR-T cells are divided into autologous and allogeneic CAR-T cells. At present, CAR-T therapy mainly uses autologous CAR-T cells.

In recent years, the progress of autologous CAR-T cell therapy in hematological tumors has inspired scientists to extend this technology to the treatment of solid tumors. However, the current progress in the treatment of solid tumors is relatively slow. But in the future, with the discovery of more targets and the development of clinical trials, solid tumors are expected to become the main treatment area for CAR-T. At present, JW (Cayman) Therapeutics is laying out more innovative products to officially enter the field of cell therapy for solid tumors.

This report presents a comprehensive overview of the global Autologous CAR-T Cell Therapy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Target: CD19
• Target: BCMA

Segment by Application

• Hematological Tumors
• Solid Tumor

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Autologous CAR-T Cell Therapy market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hematological Tumors, Solid Tumor evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact